hsa04218 |
Cellular senescence |
28 |
156 |
1.27 |
2.30 × 10−23
|
hsa05203 |
Viral carcinogenesis |
29 |
183 |
1.21 |
3.47 × 10−23
|
hsa04110 |
Cell cycle |
25 |
123 |
1.32 |
2.38 × 10−22
|
hsa04114 |
Oocyte meiosis |
23 |
116 |
1.31 |
2.13 × 10−20
|
hsa05169 |
Epstein–Barr virus infection |
24 |
194 |
1.11 |
4.01 × 10−17
|
hsa05205 |
Proteoglycans in cancer |
23 |
195 |
1.08 |
4.79 × 10−16
|
hsa04650 |
Natural killer cell-mediated cytotoxicity |
19 |
124 |
1.2 |
3.96 × 10−15
|
hsa04068 |
FoxO signaling pathway |
19 |
130 |
1.18 |
7.58 × 10−15
|
hsa04750 |
Inflammatory mediator regulation of TRP channels |
17 |
92 |
1.28 |
8.12 × 10−15
|
hsa05167 |
Kaposi’s sarcoma-associated herpesvirus infection |
21 |
183 |
1.07 |
1.30 × 10−14
|
hsa04720 |
Long-term potentiation |
15 |
64 |
1.38 |
1.77 × 10−14
|
hsa05161 |
Hepatitis B |
19 |
142 |
1.14 |
2.19 × 10−14
|
hsa05206 |
MicroRNAs in cancer |
19 |
149 |
1.12 |
4.49 × 10−14
|
hsa04370 |
VEGF signaling pathway |
14 |
59 |
1.39 |
1.11 × 10−13
|
hsa04660 |
T cell receptor signaling pathway |
16 |
99 |
1.22 |
2.39 × 10−13
|
hsa04012 |
ErbB signaling pathway |
15 |
83 |
1.27 |
3.37 × 10−13
|
hsa04611 |
Platelet activation |
17 |
123 |
1.15 |
3.37 × 10−13
|
hsa04921 |
Oxytocin signaling pathway |
18 |
149 |
1.09 |
4.19 × 10−13
|
hsa04115 |
p53 signaling pathway |
14 |
68 |
1.33 |
4.53 × 10−13
|
hsa05200 |
Pathways in cancer |
29 |
515 |
0.76 |
6.20 × 10−13
|
hsa05166 |
HTLV-I infection |
21 |
250 |
0.94 |
1.82 × 10−12
|
hsa04933 |
AGE-RAGE signaling pathway in diabetic complications |
15 |
98 |
1.2 |
2.24 × 10−12
|
hsa04510 |
Focal adhesion |
19 |
197 |
1 |
2.57 × 10−12
|
hsa04659 |
Th17 cell differentiation |
15 |
102 |
1.18 |
3.46 × 10−12
|
hsa05031 |
Amphetamine addiction |
13 |
65 |
1.31 |
3.95 × 10−12
|
hsa04728 |
Dopaminergic synapse |
16 |
128 |
1.11 |
4.97 × 10−12
|
hsa04658 |
Th1 and Th2 cell differentiation |
14 |
88 |
1.21 |
7.29 × 10−12
|
hsa05165 |
Human papillomavirus infection |
22 |
317 |
0.85 |
1.27 × 10−11
|
hsa04914 |
Progesterone-mediated oocyte maturation |
14 |
94 |
1.19 |
1.52 × 10−11
|
hsa04310 |
Wnt signaling pathway |
16 |
143 |
1.06 |
2.02 × 10−11
|
hsa04390 |
Hippo signaling pathway |
16 |
152 |
1.04 |
4.56 × 10−11
|
hsa04062 |
Chemokine signaling pathway |
17 |
181 |
0.99 |
5.10 × 10−11
|
hsa04917 |
Prolactin signaling pathway |
12 |
69 |
1.25 |
1.03 × 10−10
|
hsa04662 |
B cell receptor signaling pathway |
12 |
71 |
1.24 |
1.35 × 10−10
|
hsa04919 |
Thyroid hormone signaling pathway |
14 |
115 |
1.1 |
1.47 × 10−10
|
hsa04064 |
NF-kappa B signaling pathway |
13 |
93 |
1.16 |
1.57 × 10−10
|
hsa04270 |
Vascular smooth muscle contraction |
14 |
119 |
1.08 |
2.11 × 10−10
|
hsa04360 |
Axon guidance |
16 |
173 |
0.98 |
2.24 × 10−10
|
hsa05162 |
Measles |
14 |
133 |
1.04 |
7.76 × 10−10
|
hsa05223 |
Non-small cell lung cancer |
11 |
66 |
1.23 |
9.08 × 10−10
|
hsa04666 |
Fc gamma R-mediated phagocytosis |
12 |
89 |
1.14 |
1.18 × 10−9
|
hsa04380 |
Osteoclast differentiation |
13 |
124 |
1.03 |
3.48 × 10−9
|
hsa01521 |
EGFR tyrosine kinase inhibitor resistance |
11 |
78 |
1.16 |
4.18 × 10−9
|
hsa04010 |
MAPK signaling pathway |
18 |
293 |
0.8 |
5.87 × 10−9
|
hsa04931 |
Insulin resistance |
12 |
107 |
1.06 |
7.37 × 10−9
|
hsa04910 |
Insulin signaling pathway |
13 |
134 |
1 |
7.61 × 10−9
|
hsa04724 |
Glutamatergic synapse |
12 |
112 |
1.04 |
1.14 × 10−8
|
hsa04151 |
PI3K-Akt signaling pathway |
19 |
348 |
0.75 |
1.17 × 10−8
|
hsa04912 |
GnRH signaling pathway |
11 |
88 |
1.11 |
1.17 × 10−8
|
hsa04664 |
Fc epsilon RI signaling pathway |
10 |
67 |
1.19 |
1.30 × 10−8
|
hsa04071 |
Sphingolipid signaling pathway |
12 |
116 |
1.03 |
1.51 × 10−8
|
hsa04722 |
Neurotrophin signaling pathway |
12 |
116 |
1.03 |
1.51 × 10−8
|
hsa01522 |
Endocrine resistance |
11 |
95 |
1.08 |
2.24 × 10−8
|
hsa04014 |
Ras signaling pathway |
15 |
228 |
0.83 |
5.08 × 10−8
|
hsa04210 |
Apoptosis |
12 |
135 |
0.96 |
6.74 × 10−8
|
hsa05152 |
Tuberculosis |
13 |
172 |
0.89 |
1.01 × 10−7
|
hsa04540 |
Gap junction |
10 |
87 |
1.07 |
1.11 × 10−7
|
hsa05221 |
Acute myeloid leukemia |
9 |
66 |
1.15 |
1.42 × 10−7
|
hsa05214 |
Glioma |
9 |
68 |
1.13 |
1.74 × 10−7
|
hsa05222 |
Small cell lung cancer |
10 |
92 |
1.05 |
1.74 × 10−7
|
hsa01524 |
Platinum drug resistance |
9 |
70 |
1.12 |
2.13 × 10−7
|
hsa04215 |
Apoptosis—multiple species |
7 |
31 |
1.37 |
2.13 × 10−7
|
hsa04926 |
Relaxin signaling pathway |
11 |
130 |
0.94 |
3.72 × 10−7
|
hsa04015 |
Rap1 signaling pathway |
13 |
203 |
0.82 |
5.46 × 10−7
|
hsa04960 |
Aldosterone-regulated sodium reabsorption |
7 |
37 |
1.29 |
5.77 × 10−7
|
hsa04668 |
TNF signaling pathway |
10 |
108 |
0.98 |
6.23 × 10−7
|
hsa04261 |
Adrenergic signaling in cardiomyocytes |
11 |
139 |
0.91 |
6.58 × 10−7
|
hsa05145 |
Toxoplasmosis |
10 |
109 |
0.98 |
6.58 × 10−7
|
hsa04725 |
Cholinergic synapse |
10 |
111 |
0.97 |
7.54 × 10−7
|
hsa05120 |
Epithelial cell signaling in Helicobacter pylori infection |
8 |
66 |
1.1 |
1.53 × 10−6
|
hsa04340 |
Hedgehog signaling pathway |
7 |
46 |
1.2 |
1.97 × 10−6
|
hsa04961 |
Endocrine and other factor-regulated calcium reabsorption |
7 |
47 |
1.19 |
2.22 × 10−6
|
hsa04066 |
HIF-1 signaling pathway |
9 |
98 |
0.98 |
2.44 × 10−6
|
hsa04520 |
Adherens junction |
8 |
71 |
1.06 |
2.44 × 10−6
|
hsa04916 |
Melanogenesis |
9 |
98 |
0.98 |
2.44 × 10−6
|
hsa05225 |
Hepatocellular carcinoma |
11 |
163 |
0.84 |
2.56 × 10−6
|
hsa04621 |
NOD-like receptor signaling pathway |
11 |
166 |
0.83 |
2.99 × 10−6
|
hsa05014 |
Amyotrophic lateral sclerosis (ALS) |
7 |
50 |
1.16 |
2.99 × 10−6
|
hsa05220 |
Chronic myeloid leukemia |
8 |
76 |
1.04 |
3.62 × 10−6
|
hsa05020 |
Prion diseases |
6 |
33 |
1.27 |
4.44 × 10−6
|
hsa04020 |
Calcium signaling pathway |
11 |
179 |
0.8 |
5.69 × 10−6
|
hsa04670 |
Leukocyte transendothelial migration |
9 |
112 |
0.92 |
6.16 × 10−6
|
hsa04726 |
Serotonergic synapse |
9 |
112 |
0.92 |
6.16 × 10−6
|
hsa04723 |
Retrograde endocannabinoid signaling |
10 |
148 |
0.84 |
7.20 × 10−6
|
hsa04727 |
GABAergic synapse |
8 |
88 |
0.97 |
9.28 × 10−6
|
hsa04934 |
Cushing’s syndrome |
10 |
153 |
0.83 |
9.30 × 10−6
|
hsa04924 |
Renin secretion |
7 |
63 |
1.06 |
1.09 × 10−5
|
hsa04024 |
cAMP signaling pathway |
11 |
195 |
0.76 |
1.14 × 10−5
|
hsa04657 |
IL-17 signaling pathway |
8 |
92 |
0.95 |
1.20 × 10−5
|
hsa04022 |
cGMP-PKG signaling pathway |
10 |
160 |
0.81 |
1.28 × 10−5
|
hsa04140 |
Autophagy—animal |
9 |
125 |
0.87 |
1.28 × 10−5
|
hsa04630 |
Jak-STAT signaling pathway |
10 |
160 |
0.81 |
1.28 × 10−5
|
hsa04713 |
Circadian entrainment |
8 |
93 |
0.95 |
1.28 × 10−5
|
hsa05146 |
Amoebiasis |
8 |
94 |
0.94 |
1.32 × 10−5
|
hsa05215 |
Prostate cancer |
8 |
97 |
0.93 |
1.62 × 10−5
|
hsa05231 |
Choline metabolism in cancer |
8 |
98 |
0.92 |
1.72 × 10−5
|
hsa04371 |
Apelin signaling pathway |
9 |
133 |
0.84 |
1.94 × 10−5
|
hsa04930 |
Type II diabetes mellitus |
6 |
46 |
1.13 |
2.04 × 10−5
|
hsa03450 |
Non-homologous end-joining |
4 |
13 |
1.5 |
3.50 × 10−5
|
hsa04072 |
Phospholipase D signaling pathway |
9 |
145 |
0.81 |
3.61 × 10−5
|
hsa05226 |
Gastric cancer |
9 |
147 |
0.8 |
3.96 × 10−5
|
hsa05210 |
Colorectal cancer |
7 |
85 |
0.93 |
5.70 × 10−5
|
hsa04217 |
Necroptosis |
9 |
155 |
0.78 |
5.77 × 10−5
|
hsa04730 |
Long-term depression |
6 |
60 |
1.01 |
7.67 × 10−5
|
hsa04925 |
Aldosterone synthesis and secretion |
7 |
93 |
0.89 |
9.48 × 10−5
|
hsa04530 |
Tight junction |
9 |
167 |
0.74 |
9.70 × 10−5
|
hsa05131 |
Shigellosis |
6 |
63 |
0.99 |
9.70 × 10−5
|
hsa05010 |
Alzheimer’s disease |
9 |
168 |
0.74 |
9.98 × 10−5
|
hsa05164 |
Influenza A |
9 |
168 |
0.74 |
9.98 × 10−5
|
hsa05160 |
Hepatitis C |
8 |
131 |
0.8 |
0.00011 |
hsa03440 |
Homologous recombination |
5 |
40 |
1.11 |
0.00012 |
hsa04922 |
Glucagon signaling pathway |
7 |
100 |
0.86 |
0.00014 |
hsa05140 |
Leishmaniasis |
6 |
70 |
0.95 |
0.00016 |
hsa05168 |
Herpes simplex infection |
9 |
181 |
0.71 |
0.00016 |
hsa04971 |
Gastric acid secretion |
6 |
72 |
0.93 |
0.00018 |
hsa04918 |
Thyroid hormone synthesis |
6 |
73 |
0.93 |
0.00019 |
hsa05133 |
Pertussis |
6 |
74 |
0.92 |
0.0002 |
hsa05212 |
Pancreatic cancer |
6 |
74 |
0.92 |
0.0002 |
hsa05224 |
Breast cancer |
8 |
147 |
0.75 |
0.00021 |
hsa04150 |
mTOR signaling pathway |
8 |
148 |
0.75 |
0.00022 |
hsa05110 |
Vibrio cholerae infection |
5 |
48 |
1.03 |
0.00025 |
hsa04810 |
Regulation of actin cytoskeleton |
9 |
205 |
0.66 |
0.00037 |
hsa04911 |
Insulin secretion |
6 |
84 |
0.87 |
0.00037 |
hsa05130 |
Pathogenic Escherichia coli infection |
5 |
53 |
0.99 |
0.00037 |
hsa04970 |
Salivary secretion |
6 |
86 |
0.86 |
0.00041 |
hsa05416 |
Viral myocarditis |
5 |
56 |
0.96 |
0.00046 |
hsa05032 |
Morphine addiction |
6 |
91 |
0.83 |
0.00053 |
hsa05213 |
Endometrial cancer |
5 |
58 |
0.95 |
0.00053 |
hsa04915 |
Estrogen signaling pathway |
7 |
133 |
0.73 |
0.00063 |
hsa05418 |
Fluid shear stress and atherosclerosis |
7 |
133 |
0.73 |
0.00063 |
hsa04213 |
Longevity regulating pathway—multiple species |
5 |
61 |
0.93 |
0.00064 |
hsa04550 |
Signaling pathways regulating pluripotency of stem cells |
7 |
138 |
0.72 |
0.00076 |
hsa05211 |
Renal cell carcinoma |
5 |
68 |
0.88 |
0.001 |
hsa04920 |
Adipocytokine signaling pathway |
5 |
69 |
0.87 |
0.0011 |
hsa05219 |
Bladder cancer |
4 |
41 |
1 |
0.0013 |
hsa04211 |
Longevity regulating pathway |
5 |
88 |
0.77 |
0.0029 |
hsa04923 |
Regulation of lipolysis in adipocytes |
4 |
53 |
0.89 |
0.0031 |
hsa04120 |
Ubiquitin mediated proteolysis |
6 |
134 |
0.66 |
0.0033 |
hsa04070 |
Phosphatidylinositol signaling system |
5 |
97 |
0.72 |
0.0043 |
hsa05034 |
Alcoholism |
6 |
142 |
0.64 |
0.0043 |
hsa05142 |
Chagas disease (American trypanosomiasis) |
5 |
101 |
0.71 |
0.005 |
hsa04620 |
Toll-like receptor signaling pathway |
5 |
102 |
0.7 |
0.0051 |
hsa04932 |
Non-alcoholic fatty liver disease (NAFLD) |
6 |
149 |
0.62 |
0.0053 |
hsa05230 |
Central carbon metabolism in cancer |
4 |
65 |
0.8 |
0.0059 |
hsa03410 |
Base excision repair |
3 |
33 |
0.97 |
0.0066 |
hsa05143 |
African trypanosomiasis |
3 |
34 |
0.96 |
0.0071 |
hsa04622 |
RIG-I-like receptor signaling pathway |
4 |
70 |
0.77 |
0.0075 |
hsa05218 |
Melanoma |
4 |
72 |
0.76 |
0.0081 |
hsa05216 |
Thyroid cancer |
3 |
37 |
0.92 |
0.0087 |
hsa05202 |
Transcriptional misregulation in cancer |
6 |
169 |
0.56 |
0.0091 |
hsa04152 |
AMPK signaling pathway |
5 |
120 |
0.63 |
0.0093 |
hsa04962 |
Vasopressin-regulated water reabsorption |
3 |
44 |
0.85 |
0.0132 |
hsa05132 |
Salmonella infection |
4 |
84 |
0.69 |
0.0132 |
hsa03015 |
mRNA surveillance pathway |
4 |
89 |
0.67 |
0.0157 |
hsa04913 |
Ovarian steroidogenesis |
3 |
49 |
0.8 |
0.0171 |
hsa05030 |
Cocaine addiction |
3 |
49 |
0.8 |
0.0171 |
hsa03460 |
Fanconi anemia pathway |
3 |
51 |
0.78 |
0.0187 |
hsa05134 |
Legionellosis |
3 |
54 |
0.76 |
0.0215 |
hsa04137 |
Mitophagy—animal |
3 |
63 |
0.69 |
0.0314 |
hsa04714 |
Thermogenesis |
6 |
228 |
0.43 |
0.0314 |
hsa04927 |
Cortisol synthesis and secretion |
3 |
63 |
0.69 |
0.0314 |
hsa04976 |
Bile secretion |
3 |
71 |
0.64 |
0.0413 |
hsa04136 |
Autophagy—other |
2 |
30 |
0.84 |
0.045 |